XML 75 R60.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies (Details) - USD ($)
$ in Thousands
 1 Months Ended 9 Months Ended
Jul. 14, 2023
Jun. 30, 2023
Sep. 30, 2024
Non-cancelable commitments for product manufacturing and supply costs     $ 14,700
Pharmosa License Agreement      
Upfront license fee to be paid   $ 10,000  
Accrued additional upfront license fee   3,500  
Maximum potential development milestone payments   37,750  
Milestone payments Pharmosa is to receive per terms of the license agreement   10,000  
Pharmosa License Agreement | North America      
Maximum potential sales milestones   185,000  
Pharmosa License Agreement | Other then North America      
Maximum potential sales milestones   $ 150,000  
Chasm Technologies      
Maximum Net Sales Threshold As Basis For Payment Of Future Contingent Royalties     1,500
Net sales earned relating to payment of future contingent royalties     200
Agreement With LGM Pharma, LLC      
Purchase Commitment, Remaining Minimum Amount Committed     $ 2,700
Expiration term of agreement     5 years
Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC      
Initial term 5 years    
Termination term for FDA rejection 60 days    
Termination term for FDA delay 120 days    
Percentage of reimburse 50.00%    
Aggregate exceed $ 2,500    
Term of submission 24 months    
Initial term 12 months